Evolution of management strategies for cerebral gliomas: the effects of science and technology.
Berger
Mitchel S
MS
Department of Neurological Surgery, Brain Research Center, University of California, San Francisco, USA.
Keles
G Evren
GE
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000601:surgery*; D004260:DNA Repair / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D004720:Endonucleases / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D020868:Gene Silencing; D018773:Genes, erbB-1 / Q000187:drug effects / Q000235:genetics; D015894:Genome, Human / Q000235:genetics; D005910:Glioma / Q000188:drug therapy / Q000235:genetics / Q000601:surgery*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics
D000903:Antibiotics, Antineoplastic; D004268:DNA-Binding Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D004317:Doxorubicin; D000069347:Erlotinib Hydrochloride; C071447:ERCC1 protein, human; D004720:Endonucleases; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human